Oral News and Research

RSS

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Auxilium Licenses Stendra From Vivus For Up To $300M

...

11 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Evidence shows vaccination pilot campaigns highly successful during 2010 cholera epidemic

The deadly cholera epidemic that rocked earthquake-shattered Haiti in 2010, claiming 8,000 lives and counting, has rallied the public health community to seek water and sewer improvements that, combined with vaccination, could prevent some 89,000 future cholera infections.

11 Oct 2013

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.

10 Oct 2013

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Pancreatic cancer is one of the deadliest forms of cancer. Most of those with the disease will die within the first year of diagnosis, and just 6 percent will survive five years.

10 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Motivational interviewing may help specific subgroups of patients with schizophrenia to adhere to their antipsychotic medication, a study suggests.

8 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

ASBH proposes new method for assessing quality of clinical ethics consultants

Clinical ethicists play a vital role in hospitals and other health care systems by helping to resolve ethical conflicts that arise between patients, families, and clinicians about end-of-life care and other important medical decisions.

8 Oct 2013

New medications may be used to treat common heart-rhythm problem

An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol - a compound found in red wine and nuts - may be used to treat a common heart-rhythm problem known as atrial fibrillation.

8 Oct 2013

PMDD may shed light on complex interactions between sex hormones and mood

Improved understanding of the role of female sex hormones on the drivers and symptoms of premenstrual dysphoric disorder (PMDD) may shed light on the complex interactions between sex hormones and mood, potentially helping to explain the increased prevalence of mood disorders in women.

8 Oct 2013

Researchers examine probiotics to prevent excessive crying in infants

There still appears to be insufficient evidence to support using probiotics (Lactobacillus reuteri) to manage colic or to prevent crying in infants, especially in formula-fed babies, but it may be an effective treatment for crying infants who are breastfed exclusively and have colic, according to a study by Valerie Sung, M.P.H., of the Murdoch Childrens Research Institute and Royal Children's Hospital, Australia, and colleagues.

8 Oct 2013

LSUHSC receives $2.76M grant to study how HIV affect oral bacterial communities

Dr. Paul Fidel, the Carl Baldridge Professor and Associate Dean for Research at LSU Health Sciences Center New Orleans' School of Dentistry, is the lead principal investigator of a $2.76 million grant from the National Institute of Dental and Craniofacial Research over five years to study how HIV and antiretroviral therapy may change communities of bacteria in the mouth and what effects those changes may have on oral infections in HIV disease.

8 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

PeriodonticsLosAngeles.com helps to learn and prevent gum disease

PeriodonticsLosAngeles.com is a website created by a Los Angeles periodontist. The website is dedicated to helping you learn about periodontal disease so you can prevent it, or identify and treat the condition early, before it causes tooth loss or other major health problems.

5 Oct 2013

IOF to conduct Asia's key medical congress devoted to osteoporosis, musculoskeletal diseases

The International Osteoporosis Foundation (IOF), in cooperation with the the Hong Kong Osteoporosis Foundation and the Osteoporosis Society of Hong Kong, is staging Asia's key medical congress devoted to osteoporosis and related musculoskeletal diseases.

5 Oct 2013

Oral News and Research

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Auxilium Licenses Stendra From Vivus For Up To $300M

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Evidence shows vaccination pilot campaigns highly successful during 2010 cholera epidemic

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

Teva Cutting 5,000 Jobs In Global Restructuring

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Bayer HealthCare receives FDA approval for Adempas tablets

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

ASBH proposes new method for assessing quality of clinical ethics consultants

New medications may be used to treat common heart-rhythm problem

PMDD may shed light on complex interactions between sex hormones and mood

Researchers examine probiotics to prevent excessive crying in infants

LSUHSC receives $2.76M grant to study how HIV affect oral bacterial communities

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

PeriodonticsLosAngeles.com helps to learn and prevent gum disease

IOF to conduct Asia's key medical congress devoted to osteoporosis, musculoskeletal diseases

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News